Mesenchymal Stem Cell Timing for Skeletal Muscle Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for skeletal muscle regeneration using mesenchymal stem cells (MSCs) are limited by the need for delayed transplantation due to the hostile microenvironment after muscle injury, which can reduce the effectiveness of MSCs in promoting regeneration and is inconvenient for clinical applications.
Innovation Solution
Administering MSCs immediately or shortly after muscle injury, within 72 hours, preferably within 24 hours, to enhance functional recovery and structural regeneration, while reducing pain and scar formation, by using autologous or allogeneic MSCs isolated and characterized by specific markers, and delivering them locally to the injury site via injection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If MSCs are transplanted immediately after muscle injury, then the treatment is more convenient for clinical applications and time is reduced, but the hostile microenvironment reduces the effectiveness of MSCs in promoting regeneration
Solution Approach 1:
The patent applies preliminary action by administering MSCs immediately after muscle injury, before the hostile microenvironment fully develops. This timing strategy captures the early regenerative window when the microenvironment is still favorable, eliminating the need for delayed transplantation while maintaining high effectiveness. The MSCs are introduced at the optimal moment to maximize their regenerative potential.
Solution Approach 2:
The patent changes the temporal parameter of MSC transplantation from delayed (conventional approach) to immediate (within 24 hours). This parameter change transforms the treatment protocol to leverage the naturally occurring early regenerative phase, converting a previously suboptimal timing into a therapeutic advantage that maintains effectiveness while reducing time loss.
2Reliability
If MSCs are transplanted delayed (one week after injury) to avoid hostile microenvironment, then regenerative effectiveness is maintained, but clinical convenience is reduced and rehabilitation time is extended
Solution Approach 1:
By performing MSC transplantation as a preliminary action immediately following injury, the patent eliminates the need for a separate delayed procedure. This integrates the regenerative therapy into the acute injury management phase, improving clinical convenience by reducing the number of patient visits and procedural delays while maintaining regenerative effectiveness.
Solution Approach 2:
The patent merges the MSC transplantation procedure with the acute injury treatment phase, combining two previously separate events (injury and cell therapy) into a single integrated intervention. This consolidation improves clinical workflow and patient convenience by eliminating the intermediate waiting period while achieving the same regenerative outcomes.
3Productivity
If MSCs are transplanted immediately after injury, then rehabilitation is accelerated and functional recovery is improved, but the hostile microenvironment may reduce MSC survival and integration
Solution Approach 1:
The patent converts the previously harmful early inflammatory microenvironment into a beneficial context by introducing MSCs during this phase. The MSCs modulate the inflammatory response, transforming the hostile environment into a pro-regenerative one. This approach leverages the natural inflammatory cascade while simultaneously protecting and guiding it toward productive regeneration, improving both survival and functional outcomes.
Solution Approach 2:
The MSCs act as intermediaries between the injured muscle tissue and the immune/inflammatory response. They mediate the interaction between the hostile microenvironment and regenerative processes, suppressing harmful inflammation while promoting constructive repair. This intermediary role allows immediate transplantation to succeed despite the initially adverse conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables effective muscle regeneration, improving muscle contraction forces, reducing pain, and accelerating rehabilitation by leveraging the regenerative potential of MSCs in the immediate post-injury environment, overcoming the limitations of delayed transplantation and enhancing wound healing and functional recovery.
Implementation Method 1
MSCs exhibit a high proliferation potential and lower donor site morbidity when compared to muscle-derived cells, thus rendering them an ideal candidate for clinical application in muscle regeneration
Implementation Method 2
Mechanisms of this stimulation are on the one hand a secretion of trophic factors and of immunomodulatory factors and on the other hand a contribution to contractile muscle fibers by the progenitor cells
Implementation Method 3
A part of these cells are capable of differentiating into specific types of mesenchymal or connective tissues including adipose, osseous, cartilaginous, muscular tissue and elastic and fibrous connective tissues
Data Source
AI summary
The present invention relates to a therapeutic substance and/or medicament and methods relating to the use of said substance and/or medicament for skeletal muscle regeneration using mesenchymal stem cells (MSCs) which can be applied directly or shortly after muscle damage or injury.